EGFR+ Lung Cancer

Consolidation Therapy for Locally Advanced NSCLC

A supplemental biologics license application has been accepted by the FDA seeking approval for the combination of nivolumab plus ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden  ≥10 mutations per megabase, according to Bristol-Myers Squibb, the manufacturer of both immune checkpoint inhibitors.

The Hutchinson Institute for Cancer Outcomes Research released the first Community Care Cancer in Washington State: Quality and Cost Report to provide transparency for patients and health providers, establishing a more value-based care model.

Osimertinib (Tagrisso) has been approved by The European Commission as a frontline treatment for patients with&nbsp;<em>EGFR</em>-mutant locally-advanced or metastatic non&ndash;small cell lung cancer. The approval is based on data&nbsp;from the phase III FLAURA trial.

Robert L. Ferris, MD, PhD, Physician Editor-In-Chief of the Journal of Targeted Therapies, discusses&nbsp;genomic rearrangements and the allelic fraction of that genomic rearrangement as a major component of an individual&rsquo;s cancer.

The 2018 ASCO Annual Meeting was a great success, with over 40,000 people in attendance and over 5000 abstracts presented from June 1-5 in Chicago, Illinois. Data from several phase III trials in lung cancer were presented, with especially significant results in non&ndash;small cell lung cancer. Other big areas during this year&rsquo;s meeting included breast, gastrointestinal, genitourinary, and hematologic cancers.

Upfront treatment with the combination of bevacizumab (Avastin) and erlotinib (Tarceva) is superior to erlotinib alone as for patients with non&ndash;small cell lung cancer harboring<em> EGFR</em> mutations, according to results of a preplanned interim analysis of the phase III study known as NEJ026.

Julie R. Brahmer, MD, associate professor of oncology and co-director of the Upper Aerodigestive Department at the Bloomberg Kimmel Institute for Cancer Immunotherapy, John Hopkins Medicine, discusses the change in standard of care for patients with stage III non&ndash;small cell lung cancer. Durvalumab was recently approved by the FDA as a consolidation therapy for patients with stage III&nbsp;locally-advanced, unresectable NSCLC who had not progressed following standard chemoradiotherapy.

The investigational second-generation tyrosine kinase inhibitor dacomitinib demonstrated an improved median overall survival of 34.1 months compared to 26.8 months with&nbsp;gefitinib as a first-line treatment for patients with advanced,&nbsp;<em>EGFR</em>-mutant non&ndash;small cell lung cancer, according to data from a open-label, phase III trial presented at the 2018 ASCO Annual Meeting.¹

Overall survival improved with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel versus a treatment regimen of bevacizumab and chemotherapy alone in patients with advanced wild-type nonsquamous non&ndash;small cell lung cancer.

According to findings of an early study presented at the 2018 ASCO Annual Meeting, the combination of pegilodecakin and a PD-1 inhibitor demonstrated an overall response rate of 41% in patients with advanced non&ndash;small cell lung cancer.&nbsp;

According to the phase III KEYNOTE-407 trial, when pembrolizumab was added to frontline carboplatin/paclitaxel or nab-paclitaxel, the combination reduced the risk of death by 36% compared with chemotherapy alone for patients with metastatic squamous non&ndash;small cell lung cancer. These results were presented at the 2018 ASCO Annual Meeting.